Thymosin-α1 and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase

Journal of Viral Hepatitis

Volumn 9, Issue 4, 2002, Pages 280-287

  Lau, George K K ^a   Nanji, A ^a   Hou, J ^c   Fong, D Y T ^b   Au, W S ^b   Yuen, S T ^a   Lin, M ^b   Kung, H F ^b   Lam, S K ^a  

^a QUEEN MARY HOSPITAL   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c FIRST MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Famciclovir; HBV; Immune tolerant; Thymosin 1

Indexed keywords

CD4 ANTIGEN; CYTOKINE; FAMCICLOVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; IMMUNOMODULATING AGENT; NUCLEOSIDE ANALOG; RECOMBINANT ANTIGEN; THYMOSIN ALPHA1; VIRUS DNA; 2 AMINOPURINE; ANTIVIRUS AGENT; DRUG DERIVATIVE; HEPATITIS B CORE ANTIGEN; IMMUNOLOGICAL ADJUVANT; THYMOSIN;

ADULT; ANTIGEN DETECTION; ARTICLE; CELL PROLIFERATION; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; HEADACHE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN DETERMINATION; SEROCONVERSION; SEROLOGY; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TREATMENT OUTCOME; VIRUS CORE; ADOLESCENT; BIOSYNTHESIS; BLOOD; CELL CULTURE; CELL DIVISION; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECT; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; MIDDLE AGED; TIME;

2-AMINOPURINE; ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ANTIVIRAL AGENTS; CELL DIVISION; CELLS, CULTURED; CYTOKINES; DNA, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B CORE ANTIGENS; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNE TOLERANCE; MALE; MIDDLE AGED; T-LYMPHOCYTES; THYMOSIN; TIME FACTORS;

EID: 0036633685     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.2002.00361.x     Document Type: Article

References (46)

1. Malik AH, Lee WM. Chronic hepatitis B virus infection. Treatment strategies for the next millennium. Ann Intern Med 2000; 132: 723-731.
2. Lok ASF. Treatment of chronic hepatitis B. J Viral Hepatitis 1994; 1: 105-124.
3. Leung NWY, Lai CL, Chang TT et al. Three year lamivudine therapy in chronic HBV [Abstract]. J Hepatol 1999; 30: 59.
4. Lok AS. Natural history and control of perinatally acquired hepatitis B virus infection. Dig Dis 1992; 10: 46-52.
5. Chu CM. Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol 2000; 15 (Suppl.): E25-30.
6. Chisari FV, Ferrari C. Hepatitis B virus immunopathology. Springer Semin Immunopathol 1995; 17: 261-281.
7. Bertoletti A, D'Elios MM, Boni C et al. Different cytokine profiles of intraphepatic T cells in chronic hepatitis B and hepatitis C virus infections. Gastroenterology 1997; 112: 193-199.
8. Jung MC, Hartmann B, Gerlach JT et al. Virus-specific lymphokine production differs quantitatively but not qualitatively in acute and chronic hepatitis B infection. Virology 1999; 261: 165-172.
9. Penna A, Del Prete G, Cavalli A et al. Predominant T-helper 1 cytokine profile of hepatitis B virus nucleocapsid-specific T cells in acute self-limited hepatitis B. Hepatology 1997; 25: 1022-1027.
10. Maruyama T, McLachlan A, Iino S, Koike K, Kurokawa K, Milich DR. The serology of chronic hepatitis B infection revisited. J Clin Invest 1993; 91: 2586-2595.
11. Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999; 284: 825-829.
12. Shaw T, Locarnini S. Combination chemotherapy for hepatitis B virus: The final solution? Hepatology 2000; 32: 430-432.
13. Schalm SW, Heathcote J, Cianciara J et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: A randomised trial. Gut 2000; 46: 562-568.
14. Lau GKK, Tsiang M, Hou J et al. Combination therapy with lamivudine and famciclovir for chronic hepatitis B infected Chinese: A viral dynamics study. Hepatology 2000; 32: 394-399.
15. Liaw YF, Tsai SL, Chien RN, Yeh CT, Chu CM. Prednisolone priming enhances Th1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B. Hepatology 2000; 32: 604-609.
16. Korba BE, Milman G. A cell culture assay for compounds which inhibit hepatitis B virus replication. Antiviral Res 1991; 15: 217-228.
17. Trepo C, Jezek P, Atkinson G, Boon R, Young C. Famciclovir in chronic hepatitis B. Results of a dose-finding study. J Hepatol 2000; 32: 1011-1018.
18. de Man RA, Marcellin P, Habal F et al. A randomized, placebo-controlled study to evaluate the efficacy of 12-month famciclovir treatment in patients with chronic hepatitis B e antigen-positive hepatitis B. Hepatology 2000; 32: 413-417.
19. Sztein MB, Serrate SA, Goldstein AL. Modulation of interleukin 2 receptor expression on normal human lymphocytes by thymic hormones. Proc Natl Acad Sci USA 1986; 83: 6107-6111.
20. Serrate SA, Schulof RS, Leonidas L, Goldstein AL, Sztein MB. Modulation of human natural killer cell cytotoxic activity, lymphokine production, and interleukin 2 receptor expression by thymic hormones. J Immunol 1987; 139: 2338-2343.
21. Chien RN, Liaw YF, Chen TC, Yeh CT, Sheen IS. Efficacy of thymosin alpha1 in patients with chronic hepatitis B. A randomized, controlled trial. Hepatology 1998; 27: 1383-1387.
22. Mutchnick MG, Lindsay KL, Schiff ER et al. Thymosin alpha1 treatment of chronic hepatitis B. Results of a phase III multicentre, randomized, double-blind and placebo-controlled study. J Viral Hepat 1999; 6: 397-403.
23. Urdea M, Horn ST, Fultz TJ et al. Branched DNA amplification multimers for the sensitive, direct detection of human hepatitis viruses. Nucl Acids Res Symp Series 1991; 24: 197-200.
24. Lau GKK, Lok ASF, Liang RHS et al. Clearance of HBsAg after bone marrow transplantation: Role of adoptive immunity transfer. Hepatology 1997; 25: 1497-1501.
25. Lindh M, Andersson AS, Gusdal A. Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus large-scale analysis using a new genotyping method. J Infect Dis 1997; 175: 1285-1293.
26. Knodell MC, Ishak KG, Black WC et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-435.
27. Wu PC, Fang JWS, Lai CL, Lau SKH, Lo CK. Hepatic expression of hepatitis B virus genome in chronic hepatitis B virus infection. Am J Clin Pathol 1996; 105: 87-95.
28. Rossol S, Marinos G, Carucci P, Singer MV, Williams R, Naoumov NV. Interleukin-12 induction of Th1 cytokines is important for viral clearance in chronic hepatitis B. J Clin Invest 1997; 99: 3025-3033.
29. Milich DR, Jones JE, Hughes JL, Price J, Raney AK, McLachlan A. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero? Proc Natl Acad Sci USA 1990; 87: 6599-6603.
30. Chu CM. Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma. J Gastrol Hepatol 2000; 15 (Suppl.): E25-30.
31. Liaw YF, Leung NW, Chang TT et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000; 119: 172-180.
32. Hoofnagle JH, Peters M, Mullen KD et al. Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B. Gastroenterology 1988; 95: 1318-1325.
33. Perrillo RP, Schiff ER, Davis GL et al. A randonmized, controlled trial of interferon alfa-2b alone and after prednisolone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990; 323: 295-301.
34. Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology 1989; 10: 761-763.
35. Lok AS. Treatment of chronic hepatitis B. J Viral Hepat 1994; 1: 105-124.
36. Lok ASF, Wu PC, Lai CL et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 1992; 102: 2091-1997.
37. Farrell GC, Liaw YF. Towards consensus on the control of chronic hepatitis B and hepatitis C in the Asia-Pacific region. J Gastroenterol Hepatol 2000; 15 (Suppl): E1-2.
38. Boni C, Bertoletti A, Penna A et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998; 102: 968-975.
39. Boni C, Penna A, Ogg GS et al. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B. New perspectives for immune therapy. Hepatology 2001; 33: 963-971.
40. Carding SR, Allan W, McMickle A, Doherty PC. Activation of cytokine genes in T cells during primary and secondary murine influenza pneumonia. J Exp Med 1993; 177: 475-482.
41. Ramsay AJ, Ruby J, Ramshaw IA. A case for cytokines as effector molecules in the resolution of virus infection. Immunol Today 1993; 14: 155-157.
42. Yamamura M, Uyemura K, Deans RJ et al. Defining protective responses to pathogens: Cytokine profiles in leprosy lesions. Science 1991; 254: 277-279.
43. Scott P, Natovitz P, Coffman RL, Pearce E, Sher A. Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens. J Exp Med 1988; 168: 1675-1684.
44. Heinzel FP, Sadick MD, Holaday BJ, Coffman RL, Locksley RM. Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. J Exp Med 1989; 169: 59-72.
45. Andreone P, Cursaro C, Gramenzi A et al. A randomized controlled trial of thymosin-alpha1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody- and hepatitis B virus DNA-positive chronic hepatitis B. Hepatology 1996; 24: 774-777.
46. Mutchick MG, Appelman HD, Chung HT et al. Thymosin treatment of chronic hepatitis B: A placebo-controlled pilot trial. Hepatology 1991; 14: 409-415.